Limited-stage vs extensive-stage (SCLC)
Small-cell lung cancer is split into disease that fits in one radiation field (limited) and disease that has spread beyond it (extensive). The first is treated to cure, the second to control.
Limited-stage (about one third of patients; roughly TNM stage I-III) is confined to one hemithorax and regional nodes and treated with concurrent chemoradiotherapy followed by durvalumab (ADRIATIC); 5-year survival 25-35%. Extensive-stage is treated with chemo-immunotherapy and, since 2025, maintenance; median survival 12-15 months. The Veterans Administration two-stage system persists alongside TNM because it maps to treatment intent.
Pages like this
not linked directly; found by shared links- IdeaMRI surveillance replaces prophylactic cranial irradiation in SCLC
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TermProphylactic cranial irradiation (PCI)
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.
- PathwayThe blood–brain barrier & brain metastasis
Shares Prophylactic cranial irradiation vs MRI surveillance, Small-cell lung cancer.